Blood Test Study for Men With High-Risk Localized Prostate Cancer
Collects blood samples from adults with high-risk localized prostate cancer before surgery.
Key facts
- Who runs it
- University of Pittsburgh
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Registry title
- Circulating Tumor DNA in High Risk Localized Prostate Cancer
- Status
- Recruiting
- People taking part
- 24 people, planned
- Started
- 23 Sept 2025
- Expected to end
- 30 Sept 2027
- Type of study
- Observational
- Record updated
- 9 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer who are willing to give blood and tumor tissue samples. The main group has high-risk cancer that has not spread far and is planned for prostate surgery.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Main group: high-risk localized prostate adenocarcinoma, defined as clinical stage cT3a or higher, Grade Group 4 or 5 (Gleason sum 8-10), and PSA 20 or higher. A second exploratory group includes men on active surveillance, men whose PSA rose after local treatment, men with hormone-sensitive metastatic cancer, and men with metastatic CRPC.
- Earlier treatment
- People receiving androgen deprivation or other systemic therapy for prostate cancer cannot join.
- Biomarker or test result
- No gene or marker result is required. People must be willing to give serial blood samples and tumor tissue for comparison with circulating tumor DNA (ctDNA).
Main reasons for not taking part
- Another primary cancer in the last 3 years, except non-melanomatous skin cancer
- Receiving androgen deprivation or other systemic therapy for prostate cancer
- A medical or social situation that could prevent following the study plan
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Must have histologically confirmed prostate cancer
- Age ≥ 18 years
- ECOG performance status of 0-1
- Must have the ability to understand and the willingness to sign a written informed consent document
- Willing to provide serial blood samples for the study
- Willing to provide tumor tissue (prostatectomy for primary cohort; prostatectomy or biopsy for exploratory cohort) for correlative studies which will compare ctDNA to tumor specimens
- Primary Cohort: High-risk localized prostate adenocarcinoma defined as one or more of the following:; o Clinical stage ≥ cT3a, Grade Group 4 or 5 (Gleason sum 8-10), and PSA ≥ 20; *Non-bulky pelvic lymphadenopathy and indeterminate findings on staging imaging (CT, bone scan, PSMA PET CT) are allowed if the surgeon believes RP is appropriate
- Exploratory Cohort: Men with a diagnosis of prostate adenocarcinoma and one of the following:; Localized prostate adenocarcinoma on active surveillance; Biochemically-recurrent prostate adenocarcinoma after definitive local therapy; Hormone-sensitive, metastatic prostate adenocarcinoma; Metastatic CRPC
Who cannot take part
- Receiving androgen deprivation or other systemic therapy for prostate cancer
- History of another primary cancer within the last 3 years, except for non-melanomatous skin cancer
- Medical condition or social situation that may preclude adherence to the protocol; -
Where in United States
- UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Brieanna Marino, MSTaking people
About the trial
What the trial wants to find out
This prospective, non-therapeutic translational biomarker study will collect blood in patients with high risk localized prostate cancer prior to prostatectomy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Circulating Tumor DNA in High Risk Localized Prostate Cancer
- Plain-language title
- Blood Test Study for Men With High-Risk Localized Prostate CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 November 2026